XML 53 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Fair Value of Options
The fair value of the stock options granted were estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
Years ended December 31,
202420232022
Expected stock price volatility57.0 %59.2 %62.1 %
Risk free interest rate4.0 %3.9 %1.7 %
Expected life of options (years) 5.605.475.34
Expected annual dividend per share$— $— $— 
Schedule of Stock Options Activity
A summary of the Company's stock options is as follows:
Number of
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Years
Aggregate
Intrinsic
Value
(in thousands)(in millions)
Options outstanding, December 31, 202114,731 $11.08 
Granted5,733 $11.53 
Exercised(660)$6.58 
Forfeited(495)$12.57 
Expired(245)$12.84 
Options outstanding, December 31, 202219,064 $11.31 
Granted5,733 $11.99 
Exercised(1,361)$7.54 
Forfeited(356)$11.59 
Expired(78)$15.09 
Options outstanding, December 31, 202323,002 $11.69 
Granted4,917 $13.52 
Exercised(957)$8.02 
Forfeited(622)$12.75 
Expired(327)$14.30 
Options outstanding, December 31, 202426,013 $12.11 5.8$5.8 
Vested and unvested expected to vest, December 31, 202424,643 $12.09 5.7$5.8 
Exercisable at December 31, 202417,464 $11.80 4.6$5.7 
Schedule of Non-Vested RSU Activity under the Plan A summary of non-vested RSU activity under the Plan is as follows:
 
Number of
Shares
Weighted
Average Grant
Date Fair
Value
Weighted
Average
Remaining
Years
Aggregate
Intrinsic
Value
 
(in thousands)
(in millions)
Non-vested units as of December 31, 20217,341 $13.90 
Granted5,048 $11.93 
Vested(2,251)$12.48 
Forfeited(421)$12.06 
Non-vested units as of December 31, 20229,717 $13.07 
Granted4,762 $13.02 
Vested(3,610)$12.21 
Forfeited(836)$11.63 
Non-vested units as of December 31, 202310,033 $13.37 
Granted4,150 $14.32 
Vested(5,107)$13.07 
Forfeited(799)$13.74 
Non-vested units as of December 31, 20248,277 $13.59 2.1$78.0 
Schedule of Equity Compensation Expenses
The following table summarizes information related to compensation expense recognized in the Company's Consolidated Statements of Operations related to the equity awards:
Years ended December 31,
(in thousands)202420232022
Research and development expense$15,969 $21,470 $25,089 
Selling, general, and administrative expense68,936 64,607 51,423 
Total equity compensation expense$84,905 $86,077 $76,512